Form 4: Akero Therapeutics Executive Catriona Yale Executes Stock Option and Sells Shares Under 10b5-1 Plan

Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Catriona Yale, the Chief Development Officer of Akero Therapeutics, Inc., executed a transaction involving the company's stock on February 18, 2025.
• Yale exercised stock options to acquire 10,000 shares of common stock at a price of $21.10 per share.
• Simultaneously, Yale sold 9,100 shares at a weighted average price of $49.79 and 900 shares at a weighted average price of $50.634.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on May 24, 2024.
• Following these transactions, Yale directly owns 95,648 shares of Akero Therapeutics common stock and holds options for 10,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-arranged plan, so it doesn't necessarily indicate a positive or negative outlook on the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Risks

• Insider selling can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of a pre-planned trading strategy.

Key Dates

Keywords

Akero Therapeutics, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Catriona Yale, AKRO